Sollpura's Future After No Vote From Panel Might Include More Trials, Adult Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Gastrointestinal Drugs Advisory Committee says in lopsided votes that Lilly's exocrine pancreatic insufficiency drug candidate Sollpura (liprotamase) lacks proof of efficacy.
You may also be interested in...
Aptalis’ Ultresa And Viokace Join Crowded Marketplace Of Pancreatic Enzyme Products
The fourth and fifth products FDA has approved to treat pancreatic insufficiency join products made by Aptalis, Janssen Pharmaceuticals and Abbott GmbH.
Can You Still Use Surrogate Markers In A Crowded Drug Class? Sollpura Panel Recommends BMI, Weight Endpoints
The troubles that Alnara Pharmaceuticals has had with its application for Sollpura (liprotamase) for exocrine pancreatic insufficiency signal the challenges that developers of other drugs in crowded classes may face at FDA.
Can You Still Use Surrogate Markers In A Crowded Drug Class? Sollpura Panel Recommends BMI, Weight Endpoints
The troubles that Alnara Pharmaceuticals has had with its application for Sollpura (liprotamase) for exocrine pancreatic insufficiency signal the challenges that developers of other drugs in crowded classes may face at FDA.